department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

IMMUNIC, INC. ($IMUX) · pharmadog

PUBLIC COMPANY

$IMUXIMMUNIC, INC.

New York, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

1

marketed

0

phase 3

1

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Phase 3

vidofludimus calcium

Relapsing Remitting Multiple Sclerosis (RRMS)

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view IMMUNIC, INC. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$IMUX

SEC CIK

0001280776

country

US

source

sec_tickers

mentioned in

0news items

entity-linker matched

$IMUX

Data sources

last refreshed 13m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Active trials

phase3Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosisactive not recruitingn=1,121
phase3Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosisactive not recruitingn=1,100
phase3A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)completedn=234
phase2Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosisactive not recruitingn=450
phase2MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)active not recruitingn=210
phase2Phase 2 Dose-finding IMU-838 for Ulcerative Colitisterminatedn=263
phase1IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancerterminatedn=18

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?